Loading...

SNDX SYNDAX PHARMACEUTICALS INC Product Launches 8-K Filing

SYND

SNDX

SYNDAX PHARMACEUTICALS INC

(SNDX)

2023 8-K

Financial Results Announcement

Financial Update

Bylaw Amendments

Financial Results

FDA Approval Announcement

Financial Statements

Financial Statements

Financial Results

Positive Trial Results

Financial Results

Royalty Sale Agreement

Financial Results Announcement

Appointment and Resignation

Financial Results Announcement

Appointment of Chief Commer...

Financial Results Announcement

Public Offering

Agreement for Stock Issuance

Updates on Clinical Programs

Financial Results Announcement

Financial Results Announcement

Product Updates

Termination of Sales Agreem...

Amendment to Certificate of...

Financial Results Announcement

Appointment and Resignation

Financial Results Announcement

Approval of 2023 Inducement...

External Links:

On July 24, 2023, Syndax Pharmaceuticals, Inc. announced the topline results from its pivotal clinical trial, AGAVE-201, of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD). The company also plans to hold a conference call regarding the announcement.

AI Assistant

SYNDAX PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.